Radiopharmaceuticals Treatment of Prostate Cancer (Xofigo)
- United Lincolnshire Teaching Hospitals NHS Trust
- East Midlands
- Direct award
- 31 December 2025 to 30 December 2027
Supply of Xofigo (radium-223 dichloride) for use in nuclear medicine prostate cancer treatment pathways. This is a direct procurement of a specific pharmaceutical product for a two-year period, ensuring continuity of supply for clinical patient care.
- Awarded value
- £106k
- As published
- Published
- 19 March 2026
- Contract length
- 24 months
- Ends 30 December 2027